ABSTRACT Neuropharmacologic probes to assess central nervous system (CNS) serotonergic responsivity (e.g., _dl_-fenfluramine) stimulate serotonergic neurotransmission, thereby causing

proportional release of pituitary-derived hormones into the circulation. Individual differences in these hormonal responses are thus thought to reflect dimensional variability in central

serotonergic activity, which may, in turn, underlie variation in serotonin-related traits of personality (e.g., impulsivity, behavioral inhibition, harm avoidance). However, the long-term

temporal stability of neuropharmacologic indices of CNS serotonergic responsivity has not previously been tested in nonpsychiatric patients. _dl_-Fenfluramine was administered here to 57

and drug concentration during the challenge, was moderately reproducible (_r_ = 0.50 for peak ΔPRL and 0.57 for PRL “area under the curve,” _p_ < .0001). These findings are consistent

with speculation that variability in indices of central serotonergic function reflects a temporally stable dimension of individual differences. SIMILAR CONTENT BEING VIEWED BY OTHERS ACUTE

EFFECTS OF INTRAVENOUS DMT IN A RANDOMIZED PLACEBO-CONTROLLED STUDY IN HEALTHY PARTICIPANTS Article Open access 23 May 2023 ACUTE DOSE-DEPENDENT EFFECTS AND SELF-GUIDED TITRATION OF

CONTINUOUS _N,N-_DIMETHYLTRYPTAMINE INFUSIONS IN A DOUBLE-BLIND PLACEBO-CONTROLLED STUDY IN HEALTHY PARTICIPANTS Article Open access 19 December 2024 ACUTE DOSE-DEPENDENT EFFECTS OF LYSERGIC

ACID DIETHYLAMIDE IN A DOUBLE-BLIND PLACEBO-CONTROLLED STUDY IN HEALTHY SUBJECTS Article Open access 15 October 2020 MAIN Although it is widely hypothesized that central nervous system

(CNS) serotonergic function varies appreciably among individuals and that such variation may partially underlie differences in trait measures of disinhibition or impulsivity (e.g., Depue and

Spoont, 1986; Soubrie 1986; Cloninger, 1987; Zuckerman, 1995), the retest reliability of interindividual variability in serotonergic function (and hence the temporal stability of this

putative neurobiologic dimension) remains unclear. Neuropharmacologic challenges are used to index serotonergic function, as reflected in the stimulated release of anterior pituitary

hormones into the circulation (Murphy et al. 1990; Yatham and Steiner, 1993). The prolactin (PRL) response to fenfluramine hydrochloride has been used commonly to index central serotonergic

responsivity in humans (Murphy et al. 1990). Fenfluramine has been favored over other agents because it potently induces presynaptic release of serotonin, blocks reuptake, and possibly

activates postsynaptic receptors (Borroni et al. 1983; Quattrone et al. 1983; Coccaro et al., 1989), thereby providing a measure of net serotonergic responsivity. With respect to retest

reliability, Coccaro et al. (1987) reported that peak ΔPRL response to fenfluramine was moderately correlated (r = 0.75) in a sample of 13 male psychiatric patients over 2 to 12 days.

Similarly, Stoff et al. (1992) demonstrated that the peak ΔPRL response to fenfluramine was reproducible (r = 0.80) across 1 week among 10 boys with conduct disorder. Because these two

studies examined patient samples (e.g., conduct disorder, major depression) in whom serotonergic function may be chronically dysregulated (e.g., Coccaro et al. 1989; Flory et al. 1998), it

remains unclear to what extent normative variability in central serotonergic responsivity also reflects a reproducible dimension of individual differences. The current study was conducted to

examine the retest reliability of the PRL response to fenfluramine in 57 nonpsychiatric patients. Participants were derived from the untreated (placebo) condition of a 6-month clinical

trial conducted to examine behavioral sequelae of a cholesterol-lowering medication (Muldoon et al. 2000). A fenfluramine challenge protocol was administered at the beginning and the end of

the treatment period. METHOD PARTICIPANTS Men and women, aged 24–60 years, were included in the clinical trial if their low density lipoprotein cholesterol (LDL-C) levels exceeded 160 mg/dl.

All participants were of good general health, and none were taking medications known to affect serotonergic responsivity or plasma prolactin concentrations, including psychotropic or

glucocorticoid medications. Four participants were taking antihypertensive medications and six were using endogenous hormones (i.e., hormone replacement therapy or oral contraceptives)

throughout the 6-month clinical trial. Medical exclusions from the clinical trial included cancer treatment within the past year, stroke, diabetes requiring pharmacological treatment,

chronic kidney or liver disease, untreated hypertension, schizophrenia, or delusional disorder. Pregnant or lactating women were also excluded from participating in the study. Fenfluramine

challenge data were available on 57 individuals, including 26 women and 31 men with an average age of 46 years (SEM = 1.0). Thirty-six percent of the participants had a baccalaureate or

higher degree, and 90 percent of the sample was employed. Fifty-one participants were Caucasian, five were African American, and one was Asian American. Nine individuals (16%) met criteria

for a current DSM-III-R Axis I diagnosis of mild to moderate severity at one or both assessments based on structured clinical interview (Structured Clinical Interview for DSM-III-R:

Non-Patient Edition [Spitzer et al., 1990]), but none were receiving treatment. Diagnoses included social phobia (_n_ = 1), simple phobia (_n_ = 1), alcohol dependence (_n_ = 3), a

nonpsychotic mood disorder (_n_ = 3), and adjustment disorder (_n_ = 1). All statistical analyses reported below retained significance on reanalysis excluding these nine individuals.

Participants provided written, informed consent, and the protocol was approved by the Institutional Review Board at the University of Pittsburgh. PROCEDURE _FENFLURAMINE CHALLENGE_ The

protocol for the challenge has been described in detail (Manuck et al. 1998). Briefly, participants reported to the laboratory in the morning after a 12-h fast. A 20-gauge, heparin-locked

catheter was introduced aseptically into a vein in the antecubital fossa. After a 30-min adaptation period, a blood sample to determine baseline (i.e., pre-administration) plasma PRL

concentration was drawn, after which _dl_-Fenfluramine hydrochloride was administered orally as a single dose of 30–60 mg in 10-mg increments to best approximate a weight relative

administration of 0.55–0.65 mg fenfluramine/kg body weight. Blood samples were drawn 60, 120, 150, 180, and 210 min later. Plasma PRL concentration was determined from each sample, and

fenfluramine and norfenfluramine concentrations during the challenge were determined from samples drawn at 150 and 210 min. All blood samples were centrifuged, separated, and frozen at −70°C

until analysis. An identical protocol was repeated after 6 months (average days = 181; SEM = 2.7]). _PRL ASSAY_ Plasma PRL levels were determined in duplicate using Immunocorp's

(Montreal, Canada) solid phase two-site immunoradiometric method. The lower limit of sensitivity of the PRL assay is 0.5 ng/ml, and the interassay coefficient of variation is 6–9%. The lower

detection limit of the fenfluramine/norfenfluramine assays is 2.0 ng/ml, and the coefficient of variation is 5.2% at 5.0 ng/ml. STATISTICAL ANALYSES Peak PRL response (ΔPRL[fen]) was

expressed as the arithmetic difference between the highest PRL concentration obtained after drug administration and pre-administration PRL concentration. The area under the response curve

(AUC PRL[fen]) was calculated using trapezoidal integration. These two indices of serotonergic responsivity were then adjusted by regression for any covariation with pre-administration PRL

concentration, sex, age, or fenfluramine and norfenfluramine concentrations during the challenge. The temporal stability of individual differences in these indices of serotonergic

responsivity was examined with Pearson correlations, computed across the 6-month interval. Among women, the challenges were performed without control for menstrual cycle phase, and, because

PRL response to fenfluramine is known to vary appreciably across the menstrual cycle (O'Keane et al. 1991), the correlations were repeated excluding premenopausal women and

postmenopausal women taking hormone replacement therapy according to a cyclic schedule (_n_ = 15). RESULTS AND DISCUSSION Baseline PRL levels, unadjusted ΔPRL[fen], and AUC PRL[fen] levels

at both assessments are presented in Table 1, for men and women separately. Because of practical constraints, we shortened the standard 5-h protocol to 3.5 h, which may account for adjusted

ΔPRL[fen] values that are somewhat lower than previous reports (e.g., Coccaro et al. 1987; Stoff et al., 1992)). As we have reported previously (Manuck et al., 1998), however, peak PRL

concentrations during abbreviated and standard protocols correlated 0.91 in a separate sample of 42 individuals who completed the 5-h protocol, indicating high concordance for peak PRL

concentrations across the two sampling intervals. Retest correlations for baseline PRL levels and the two indices of serotonergic responsivity are presented in Table 2 Baseline, or

preadministration, PRL levels were highly stable over 6 months, with a correlation of 0.88 across all participants. Adjusted Δ PRL[fen] concentrations and AUC PRL[fen] were moderately

reproducible across time in the total sample (r = 0.50 and 0.57, respectively; _p_ < .0001). When cycling women were excluded from the analyses, the retest correlations were comparable,

increasing to 0.54 (_p_ < .0001) for adjusted ΔPRL[fen] and 0.59 (_p_ < .0001) for adjusted AUC PRL[fen]. These results demonstrate moderate retest reliability for the fenfluramine

challenge when used as an index of CNS serotonergic responsivity in adults. That the results of the current study were not stronger may be due to the interval between measurements, which was

considerably longer than that of previous reports, that is, 6 months compared with 1–2 weeks in the studies reported by Coccaro et al. (1987) and Stoff et al. (1992). The results of the

current study are consistent with previous reports showing good stability of the prolactin response to fenfluramine in psychiatric patients (Coccaro et al., 1987; Stoff et al., 1992).

Participants in the current study were generally healthy, and none were receiving psychopharmacological treatment. However, all had elevated LDL-C concentrations. In the current sample, we

are unable to evaluate hypotheses linking (low) serum cholesterol to psychiatric disorders and behaviors associated with dysregulated 5-HT responsivity (e.g., depression, impulsive

aggression, suicide). It might be noted that within the restricted range of lipid concentrations present in our sample, neither the adjusted ΔPRL[fen] concentrations nor the AUC PRL[fen]

were associated with variability in total cholesterol, LDL-C, or high density lipoprotein cholesterol levels at either occasion of testing (r = −0.18–0.14). Thus, to the extent that

cholesterol varied in this sample, it was unrelated to measures of CNS serotonergic responsivity. Hormonal responses to fenfluramine are thought to represent net CNS serotonergic

responsivity, because fenfluramine both stimulates presynaptic release of serotonin and blocks reuptake. It is not clear, however, whether hormonal responses to agents that preferentially

target pre- or postsynaptic events or specific serotonin receptors are temporally stable. For example, intravenous infusion of clomipramine, which blocks serotonin reuptake, was associated

with comparable peak prolactin responses across 4 weeks in healthy men but not across 2 weeks in a separate group of healthy men (Gilmore et al., 1993). The reproducibility of hormonal

responses to selective serotonin reuptake inhibitors awaits further confirmation. To conclude, the findings of this study are consistent with speculation that interindividual variability on

indices of serotonergic function reflects a stable neurobiologic dimension of individual differences that may in turn underlie variation in serotonin-associated traits of personality or

temperament. REFERENCES * Borroni E, Ceci A, Garattini S, Mennini T . (1983): Differences between d-fenfluramine and d-norfenfluramine in serotonin presynaptic mechanisms. _J Neurochemistry_

40: 891–893 Article  CAS  Google Scholar  * Cloninger CR . (1987): A systematic method for clinical description and classification of personality variants. _Arch Gen Psychiatry_ 44: 573–588

Article  CAS  Google Scholar  * Coccaro EF, Siever LJ, Klar H, Rubenstein K, Benjamin E, Davis KL . (1987): Diminished prolactin responses to repeated fenfluramine challenge in man.

_Psychiatry Res_ 22: 257–259 Article  CAS  Google Scholar  * Coccaro EF, Siever LJ, Klar HM, Maurer G, Cochrane K, Cooper TB, Mohs RC, Davis KL . (1989): Serotonergic studies in patients

with affective and personality disorders: Correlates with suicidal and impulsive aggressive behavior. _Arch Gen Psychiatry_ 46: 587–599 Article  CAS  Google Scholar  * Depue RA, Spoont MR .

(1986): Conceptualizing a serotonin trait: A behavioral dimension of constraint. _Ann NY Acad Sci_ 487: 47–62 Article  CAS  Google Scholar  * Flory JD, Mann JJ, Manuck SB, Muldoon MF .

(1998): Recovery from major depression is not associated with normalization of serotonergic function. _Biol Psychiatry_ 43: 320–326 Article  CAS  Google Scholar  * Gilmore JH, Ruegg RG,

Ekstrom RD, Knight B, Carson SW, Mason GA, Golden RN . (1993): Altered prolactin response to clompiramine rechallenge in healthy subjects. _Biol Psychiatry_ 34: 885–888 Article  CAS  Google

Scholar  * Manuck SB, Flory JD, McCaffery JM, Matthews KA, Mann JJ, Muldoon MF . (1998): Aggression, impulsivity, and central nervous system serotonergic responsivity in a nonpatient sample.

_Neuropsychopharmacology_ 19: 287–299 Article  CAS  Google Scholar  * Muldoon MF, Barger SD, Ryan CM, Flory JD, Lehoczky JP, Matthews KA, Manuck SB . (2000): Effects of lovastatin on

cognitive function and psychological well-being. _Am J Med_ 108: 538–547 Article  CAS  Google Scholar  * Murphy DL, Mellow AM, Sunderland T, Aulakh CS, Lawlor BL, Zohar J . (1990):

Strategies for the study of serotonin in humans. In Coccaro EF, Murphy DL (eds), _Serotonin in Major Psychiatric Disorders._ Washington, DC, American Psychiatric Press, pp 3–25 Google

Scholar  * O'Keane V, O'Hanlon M, Webb M, Dinan T . (1991): _d_-Fenfluramine/prolactin response throughout the menstrual cycle: Evidence for an oestrogen-induced alteration. _Clin

Endocrinol_ 34: 289–292 Article  CAS  Google Scholar  * Quattrone A, Tedeschi G, Aguglia U, Scopacasa F, DiRenzo GF, Annunziato L . (1983): Prolactin secretion in man, a useful tool to

evaluate the activity of drugs on central 5-hydroxytryptaminergic neurons: Studies with fenfluramine. _Br J Clin Pharmacol_ 16: 471–475 Article  CAS  Google Scholar  * Soubrie P . (1986):

Reconciling the role of central serotonin neurons in humans and animal behavior. _Behav Brain Sci_ 9: 319–364 Article  Google Scholar  * Spitzer RL, Williams JBW, Gibbon M, First MB .

(1990): _Structured Clinical Interview for DSM-III-R: Non-Patient Edition_ (SCID-NP Version 10). Washington, DC,: American Psychiatric Press. Google Scholar  * Stoff DM, Pasatiempo AP, Yeung

JH, Bridger WH, Rabinovich H . (1992): Test-retest reliability of the prolactin and cortisol responses to d,l-fenfluramine challenge in disruptive behavior disorders. _Psychiatry Res_ 42:

65–72 Article  CAS  Google Scholar  * Yatham LN, Steiner M . (1993): Neuroendocrine probes of serotonergic function: A critical review. _Life Sci_ 53: 447–463 Article  CAS  Google Scholar  *

Zuckerman M . (1995): Good and bad humors: Biochemical bases of personality and its disorders. _Psycholog Sci_ 6: 325–332 Article  Google Scholar  Download references ACKNOWLEDGEMENTS This

research was supported by National Institutes of Health grant HL46328 (MFM). AUTHOR INFORMATION AUTHORS AND AFFILIATIONS * Department of Psychology, Behavioral Physiology Laboratory,

University of Pittsburgh, Pittsburgh, PA, USA Janine D Flory Ph.D & Stephen B Manuck Ph.D * Center for Clinical Pharmacology, University of Pittsburgh School of Medicine, Pittsburgh, PA,

USA Matthew F Muldoon MD, MPH Authors * Janine D Flory Ph.D View author publications You can also search for this author inPubMed Google Scholar * Stephen B Manuck Ph.D View author

publications You can also search for this author inPubMed Google Scholar * Matthew F Muldoon MD, MPH View author publications You can also search for this author inPubMed Google Scholar

CORRESPONDING AUTHOR Correspondence to Janine D Flory Ph.D. RIGHTS AND PERMISSIONS Reprints and permissions ABOUT THIS ARTICLE CITE THIS ARTICLE Flory, J., Manuck, S. & Muldoon, M.

Retest Reliability of Prolactin Response to _dl_-Fenfluramine Challenge in Adults. _Neuropsychopharmacol_ 26, 269–272 (2002). https://doi.org/10.1016/S0893-133X(01)00330-X Download citation

* Received: 07 February 2001 * Revised: 14 June 2001 * Accepted: 26 June 2001 * Published: 06 July 2001 * Issue Date: 01 February 2002 * DOI: https://doi.org/10.1016/S0893-133X(01)00330-X

SHARE THIS ARTICLE Anyone you share the following link with will be able to read this content: Get shareable link Sorry, a shareable link is not currently available for this article. Copy to

clipboard Provided by the Springer Nature SharedIt content-sharing initiative KEYWORDS * Serotonin, d,l-Fenfluramine, Retest reliability